AbbVie (ABBV) Q4 FY25 earnings call

AbbVie closed 2025 with record net sales and strong financial performance, driven by exceptional growth in its immunology and neuroscience franchises. The company exceeded its financial commitments and advanced a robust pipeline through strategic business development, positioning it for continued high single-digit revenue growth through 2029. While navigating ongoing Humira erosion and IRA pricing impacts, AbbVie remains focused on innovation and expanding its diverse portfolio.